Trial Profile
The PREDICT (Personalised RNA Interference to Enhance the Delivery of Individualised Cytotoxic and Targeted Therapeutics) Approach to Biomarker Discovery in Renal Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2012
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms S-PREDICT
- 30 Apr 2012 New trial record